Last reviewed · How we verify
iMP cells
At a glance
| Generic name | iMP cells |
|---|---|
| Also known as | "Heartcel" |
| Sponsor | Cell Therapy Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (PHASE1)
- Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Hospitalization (NA)
- Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. (PHASE2)
- Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators. (PHASE2)
- Rapid Autopsy and Procurement of Cancer Tissue
- A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (PHASE2)
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iMP cells CI brief — competitive landscape report
- iMP cells updates RSS · CI watch RSS
- Cell Therapy Ltd. portfolio CI